111 related articles for article (PubMed ID: 23582093)
1. PI3K inhibitors as novel cancer therapies: implications for cardiovascular medicine.
McLean BA; Zhabyeyev P; Pituskin E; Paterson I; Haykowsky MJ; Oudit GY
J Card Fail; 2013 Apr; 19(4):268-82. PubMed ID: 23582093
[TBL] [Abstract][Full Text] [Related]
2. New phosphatidylinositol 3-kinase inhibitors for cancer.
Bowles DW; Jimeno A
Expert Opin Investig Drugs; 2011 Apr; 20(4):507-18. PubMed ID: 21395485
[TBL] [Abstract][Full Text] [Related]
3. PI3K: a potential therapeutic target for cancer.
Chen Y; Wang BC; Xiao Y
J Cell Physiol; 2012 Jul; 227(7):2818-21. PubMed ID: 21938729
[TBL] [Abstract][Full Text] [Related]
4. The role of phosphatidylinositol 3-kinase signaling pathways in pancreatic cancer.
Sun C; Rosendahl AH; Andersson R; Wu D; Wang X
Pancreatology; 2011; 11(2):252-60. PubMed ID: 21625196
[TBL] [Abstract][Full Text] [Related]
5. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K-Akt pathway in kidney cancer.
Park JY; Lin PY; Weiss RH
Expert Rev Anticancer Ther; 2007 Jun; 7(6):863-70. PubMed ID: 17555396
[TBL] [Abstract][Full Text] [Related]
7. Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.
Geuna E; Milani A; Martinello R; Aversa C; Valabrega G; Scaltriti M; Montemurro F
Expert Opin Investig Drugs; 2015 Mar; 24(3):421-31. PubMed ID: 25645727
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic applications of PI3K inhibitors in cardiovascular diseases.
Ghigo A; Morello F; Perino A; Hirsch E
Future Med Chem; 2013 Mar; 5(4):479-92. PubMed ID: 23495693
[TBL] [Abstract][Full Text] [Related]
10. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Steingart RM; Bakris GL; Chen HX; Chen MH; Force T; Ivy SP; Leier CV; Liu G; Lenihan D; Lindenfeld J; Maitland ML; Remick SC; Tang WH
Am Heart J; 2012 Feb; 163(2):156-63. PubMed ID: 22305831
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
[TBL] [Abstract][Full Text] [Related]
13. Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
Wee S; Lengauer C; Wiederschain D
Curr Opin Oncol; 2008 Jan; 20(1):77-82. PubMed ID: 18043260
[TBL] [Abstract][Full Text] [Related]
14. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
Brachmann S; Fritsch C; Maira SM; García-Echeverría C
Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
[TBL] [Abstract][Full Text] [Related]
15. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
16. Targeting PI3K signaling in cancer: Challenges and advances.
De Santis MC; Gulluni F; Campa CC; Martini M; Hirsch E
Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):361-366. PubMed ID: 30946868
[TBL] [Abstract][Full Text] [Related]
17. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
18. Targeting PI3K-AKT pathway for cancer therapy.
Lu Y; Wang H; Mills GB
Rev Clin Exp Hematol; 2003 Jun; 7(2):205-28. PubMed ID: 14763163
[TBL] [Abstract][Full Text] [Related]
19. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
Dasanu CA; Padmanabhan P; Clark BA; Do C
Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
